NASDAQ · FENC
Healthcare · Biotechnology
$11.65
Down-$0.35 (-3.00%)
Updated Sep 10, 2026, 11:28 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
FENC closed at $11.65 after 20 trading sessions, down 1.52% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $12.35 | $12.45 | $11.42 | $11.65 | 348.66K |
| Sep 8, 2026 | $12.16 | $12.53 | $12.0823 | $12.45 | 256.28K |
| Sep 4, 2026 | $12.45 | $12.60 | $12.29 | $12.39 | 212.44K |
| Sep 3, 2026 | $12.42 | $12.79 | $12.13 | $12.55 | 296.1K |
| Sep 2, 2026 | $12.04 | $12.3899 | $11.87 | $12.31 | 292.04K |
| Sep 1, 2026 | $12.35 | $12.4199 | $11.8815 | $12.03 | 348.05K |
| Aug 31, 2026 | $12.29 | $12.685 | $12.075 | $12.35 | 508.68K |
| Aug 28, 2026 | $11.71 | $12.505 | $11.60 | $12.27 | 421.81K |
| Aug 27, 2026 | $12.13 | $12.1928 | $11.61 | $11.77 | 296.83K |
| Aug 26, 2026 | $11.70 | $12.28 | $11.295 | $12.17 | 250.95K |
| Aug 25, 2026 | $11.44 | $11.8799 | $11.44 | $11.71 | 198.35K |
| Aug 24, 2026 | $11.29 | $11.47 | $10.88 | $11.40 | 218.9K |
| Aug 21, 2026 | $11.47 | $11.65 | $11.22 | $11.29 | 210.74K |
| Aug 20, 2026 | $11.79 | $11.9734 | $11.17 | $11.35 | 246.21K |
| Aug 19, 2026 | $12.00 | $12.19 | $11.79 | $11.87 | 165.41K |
| Aug 18, 2026 | $11.88 | $12.02 | $11.73 | $11.87 | 129.51K |
| Aug 17, 2026 | $11.98 | $12.06 | $11.65 | $11.83 | 190.57K |
| Aug 14, 2026 | $12.09 | $12.245 | $11.70 | $11.72 | 106.94K |
| Aug 13, 2026 | $11.94 | $12.35 | $11.87 | $12.06 | 191.02K |
| Aug 12, 2026 | $12.80 | $13.25 | $11.62 | $11.83 | 358.94K |
The latest Smart Investors Daily articles mentioning FENC.
FENC research
Company profile and research snapshot.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 12, 2026 | Wedbush | Outperform | — |
| Aug 12, 2026 | B. Riley Securities | Buy | — |
| May 22, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 16, 2026 | Wedbush | Outperform | — |
Generated Sep 10, 2026, 9:25 PM
Fennec Pharmaceuticals shares declined 3.00% today despite receiving continued analyst support, suggesting broader market headwinds or profit-taking may be outweighing positive sentiment from the research community. HC Wainwright's reiterated buy rating and $16 price target indicate conviction from at least one major analyst, but the stock's weakness suggests investors may be focused on near-term challenges or waiting for concrete catalysts.
Bottom line: FENC's 3.00% decline today appears disconnected from fundamentals, given continued analyst support and a $16 price target implying significant upside potential. Investors should view this weakness as either a temporary pullback or a potential entry point if they believe in the company's pipeline and clinical prospects, but should remain vigilant for upcoming regulatory, clinical, or financial catalysts that could drive material re-rating in either direction.
Benzinga · Sep 9, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $16 price target.
Benzinga · Aug 12, 2026
B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $16 to $18.
Benzinga · Aug 12, 2026
Wedbush analyst David Nierengarten maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and raises the price target from $13 to $16.
SeekingAlpha · Aug 12, 2026
Fennec Pharma (FENC) hits near highs on PEDMARK profits, but 36x forward earnings and single-asset risk leave no margin of safety.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FENC.
